Brainscope Receives Investment From The Alzheimer’s Drug Discovery Foundation For Alzheimer's Prediction Biomarker
Round Type
Venture
RockvilleBiotechnologyHealthcareHealth CareMedicalMedical DeviceHealth DiagnosticsInvestors
Description
Brain diagnostics innovator BrainScope announced today a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s current Series B equity financing round. This investment supports the ongoing development of a new Artificial Intelligence / Machine Learning derived brain-activity based biomarker to predict future onset of Alzheimer’s. The company is also evaluating whether its trauma related, FDA-cleared brain bleed biomarker might be effective in detecting ARIAs, a serious side effect of the newly FDA approved Alzheimer’s drugs, so that patients might avoid the expensive and time-consuming multiple MRI scans that are currently recommended.
Who to call at BrainScope, and when
A new round usually means BrainScope is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day BrainScope raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BrainScope, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BrainScope raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
BrainScope raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.